Bristol Myers Squibb can select up to two innovative life-sciences and biotech start-up companies per year of active sponsorship for “Golden Tickets,” which cover the cost of one 6-foot lab bench and one resident scientist fee at LabCentral’s Kendall Square facility for one year.
Lucy Therapeutics (LucyTx) is a mitochondrial platform company currently focused on small molecule treatments for Rett syndrome and Parkinson’s disease. LucyTx’s platform has led to the discovery of targets and molecules which can improve critical mitochondrial dysfunction in these diseases and address their complex organ symptomatology. Leveraging advanced chemical matter for these targets, LucyTx can quickly answer key questions about the pathways critical for disease modification. By targeting mitochondrial outcomes, this opens the opportunity for a peripheral biomarker approach for these diseases, which are being pursued in both of the company’s programs.
Lucy Therapeutics was a year two MassNextGen awardee. The program supports women entrepreneurs in early-stage life sciences companies by providing non-dilutive grant funding and access to a network of seasoned Executive Coaches from the life sciences ecosystem.
